Introduction
============

The phosphoinositide 3-kinase (PI3K) signaling pathway, which promotes cancer cell growth and metabolism, is the most frequently mutated pathway in breast cancer. This pathway is associated with failure of clinical treatments, such as anti‒human epidermal growth factor receptor 2 (HER2) therapy and endocrine therapy, and chemotherapy resistance \[[@b1-crt-2017-598],[@b2-crt-2017-598]\]. Clinical development of several pan-PI3K inhibitors, PI3Kα subunit-specific inhibitors, PI3Kβ subunitspecific inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and PI3K/mTOR dual inhibitors is currently underway. However, the biomarkers to evaluate the efficacy of these agents still need to be elucidated.

According to The Cancer Genome Atlas network (TCGA), the percentage of *PIK3CA* mutations is 34.18%, and the percentage of *AKT1* mutations is 3.14% \[[@b3-crt-2017-598]\]. Reports of the prevalence of *PIK3CA* mutation varied among studies (15.6%-47.6%) \[[@b4-crt-2017-598]-[@b16-crt-2017-598]\], and the percentage *PIK3CA* mutation is between 15.6% and 28.3% in Chinese breast cancer patients \[[@b10-crt-2017-598],[@b11-crt-2017-598],[@b14-crt-2017-598]\]. These mutation frequencies may be underestimated. One possible reason is that most studies detected several exons with hotspot mutations via Sanger sequencing, spectrometry genotyping, or hydrolysis probe assays \[[@b4-crt-2017-598]-[@b13-crt-2017-598]\]. In the BOLERO-2 trial, tumor samples from 302 patients were analyzed via next-generation sequencing (NGS). In this trial, the percentage of *PIK3CA* mutations was 47.6%, which is within the range of the most frequently mutated genes in breast cancer \[[@b15-crt-2017-598]\]. Another possible reason is that some studies used formalin-fixed, paraffin-embedded (FFPE) tissues \[[@b7-crt-2017-598],[@b10-crt-2017-598],[@b13-crt-2017-598]\], and as preservation time increases, DNA may break down and therefore may not be amplified. In a previous study, we also detected *PIK3CA* and *AKT1* hotspot mutations using FFPE tissues from 288 breast cancer patients via Sanger sequencing. However, the amplification failure rate of a single exon was as high as 25.7%, where the frequency of *PIK3CA* mutation was only 15.6% \[[@b10-crt-2017-598]\]. Both aforementioned reasons can lead to underestimation of the *PIK3CA* mutation frequency.

In this single-center observational study, we investigated the frequency of *PIK3CA* and *AKT1* mutations in tumor tissues from 507 Chinese breast cancer patients using NGS and explored their role in tumor phenotype and disease prognosis.

Materials and Methods
=====================

1. Study patients
-----------------

All patients pathologically diagnosed with breast cancer were prospectively registered in the Breast Cancer Information Management System (BCIMS) at the West China Hospital, Sichuan University beginning in 2008. In this study, patients who had undergone surgery between 2008 and 2013 were recruited. Patients who underwent neoadjuvant chemotherapy, lacked complete clinical information, or were unable to provide enough frozen tumor tissue were excluded from this study. Ultimately, 507 patients were eligible for the *PIK3CA/AKT1* mutation test and analysis of clinical characteristics.

Clinical and pathological characteristics of 507 patients were extracted from the BCIMS ([S1 Table](#SD1-crt-2017-598){ref-type="supplementary-material"}). Immunohistochemistry (IHC) scoring for estrogen receptor (ER), progesterone receptor (PR) was conducted following the Guidelines for Testing of ER and PR in Breast Cancer \[[@b17-crt-2017-598]\]; IHC and fluorescence *in situ* hybridization scoring for human epidermal growth factor receptor-2 (HER2) was performed according to the Guidelines for HER2 Detection in Breast Cancer \[[@b18-crt-2017-598]\]. The subtypes of breast cancer were classified according to St. Gallen International Expert Consensus \[[@b19-crt-2017-598]\]. Follow-up on survival status was available until May 2017. Invasive disease-free survival (iDFS) was defined as the interval between surgery date and first relapse of cancer, death, the second primary tumor, or last follow-up \[[@b20-crt-2017-598]\]. Overall survival (OS) was defined as the interval between surgery date and patient death, or last follow-up. Among 498 patients with stage I-III breast cancer, 57 iDFS events and 36 OS events were observed.

2. Targeted DNA sequencing and bioinformatics
---------------------------------------------

Freshly frozen tumor tissues were obtained from the 507 breast cancer patients. Tumor content of ≥ 50% was qualified via pathology quality control. Tumor DNA samples were screened for variants in all coding exons of the *PIK3CA* and *AKT1* genes with a customized QIAGEN Gene Read panel, using NGS on a MiSeq system (Illumina, San Diego, CA). Whole blood or distal adjacent normal tissue were used to filter out germline variants for 24 patients in which novel *PIK3CA* variants were identified during interim data analysis.

After trimming adapters and low-quality bases (sequencing quality cutoff at Q30), reads were mapped to Human B37.3. Genomic variants were organized using the following criteria: reads uniquely mapped to the genome; mapping quality \> 15; number of mutated reads ≥ 5, and mutant allele frequency ≥ 0.01. Variants were then manually verified in the Genome Browser.

3. Statistical analysis
-----------------------

Two-tailed t test, chi-square test, and Fisher exact test were performed to assess significance of the association between variables (*PIK3CA* and *AKT* mutations) and clinical characteristics (SPSS ver. 20, IBM Corp., Armonk, NY). The Kaplan-Meier survival curve was drawn and tested by log-rank test to evaluate the differences in iDFS and OS between the variables. The effect of mutations on prognosis was analyzed by Cox multivariate risk models. A p-value of \< 0.05 was considered statistically significant.

4. Ethical statement
--------------------

This study was approved by the Clinical Test and Biomedical Ethics Committee of West China Hospital, Sichuan University. Written informed consent was provided by all patients.

Results
=======

1. Prevalence and characteristics of *PIK3CA* and *AKT* mutations
-----------------------------------------------------------------

The prevalence of *PIK3CA* and *AKT1* mutations is shown in [Table 1](#t1-crt-2017-598){ref-type="table"}. *AKT1* mutation was found in 18 patients (3.6%), and the percentage of hotspot mutations for *AKT1_E17K* was 3.4% (17/507). *PIK3CA*mutation was detected in 236 (46.5%) patients. *PIK3CA* hotspot mutations (H1047R/L, E545K, E542K) were found in 39.4% of breast cancer patients (200/507), with H1047R ranking the highest. These hotspot mutations account for 84.7% of breast cancer patients (200/236) who carry somatic *PIK3CA* variants. There were 273 mutations of *PIK3CA* in total. Thirty-five patients carried two or three mutations in *PIK3CA* ([S2 Table](#SD2-crt-2017-598){ref-type="supplementary-material"}), and 33 had concurrent hotspot mutations with 1 or 2 non-hotspot mutations. *AKT1* mutations (3 *AKT1_E17K* and 1 *AKT1_C77F*) were concurrent with *PIK3CA*\_H1047Rmutation in four patients. When *AKT1* and *PIK3CA*mutations were combined based on mutant burden, 39 patients carried two or three mutations (2MTs) ([S2 Table](#SD2-crt-2017-598){ref-type="supplementary-material"}), 211 patients had one mutation (1MT), and 257 patients carried wild-type (WT) *PIK3CA* and *AKT1*. The clinical and pathological features of patients with *PIK3CA* and *AKT1* mutations are shown in [Table 2](#t2-crt-2017-598){ref-type="table"}.

### 1) *AKT1* mutation

All patients with *AKT1*mutations were ER+/PR+/HER2-- ([Table 2](#t2-crt-2017-598){ref-type="table"}). In addition, the *AKT1* E17K mutation was significantly associated with Ki67 high expression, but was not associated with age at diagnosis, menopausal status, family history, pathological type, tumor grade, T category, lymph node stage or metastasis.

### 2) *PIK3CA* mutation

Compared to breast cancers expressing wild type *PIK3CA*, both hotspot and non-hotspot *PIK3CA* mutant cancers were more likely to be ER+, PR+, HER2-- or of the luminal B (HER2 negative) subtype ([Table 2](#t2-crt-2017-598){ref-type="table"}). *PIK3CA* mutation was not associated with age at diagnosis, menopausal status, family history, pathological type, tumor grade, T category, lymph node stage, Ki67 expression, or metastasis. No difference was observed between patients with hotspot mutations and nonhotspot mutations, except for HER2 status.

### 3) *PIK3CA/AKT1* mutation

When *AKT1* and *PIK3CA* mutations were analyzed by mutation burden, cancers with 2MTs or with 1MT were more likely to be ER+, PR+, HER2--, high Ki67, or of the luminal B (HER2 negative) subtype compared with cancers with WT *PIK3CA* and *AKT1*. When 2MTs and 1MT were sub-analyzed, no difference was observed between the two subgroups except for Ki67 expression.

2. Association of *PIK3CA* and *AKT1* mutations with survival
-------------------------------------------------------------

Survival analysis was conducted among 296 invasive stage I-III breast cancer patients with at least a 5-year follow-up. According to the tumor mutational burden of *PIK3CA/AKT1*, there were 18 patients with 2MTs, 124 cases with 1MT and 154 cases with WT. The baseline of these 296 patients is summarized in [S3 Table](#SD3-crt-2017-598){ref-type="supplementary-material"}. Both *PIK3CA* and *PIK3CA/AKT1* mutations were more frequent in cancers that were ER+, HER2--, or expressing high Ki67. The Kaplan-Meier survival curve and Cox multivariate risk models were used to evaluate the survival of patients.

### 1) Total patients (296 cases)

Regarding *PIK3CA*mutation, patients with 1MT showed better iDFS than patients with 2MTs ([Fig. 1A](#f1-crt-2017-598){ref-type="fig"}), with a relative hazard ratio (HR) of 0.344 (p=0.049) after adjustment ([Table 3](#t3-crt-2017-598){ref-type="table"}). Patients with 1MT (adjusted HR, 0.222; p=0.020) or WT *PIK3CA* (adjusted HR, 0.221; p=0.021) had better OS than patients with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 1B](#f1-crt-2017-598){ref-type="fig"}). However, there was no difference in iDFS between patients with WT and 2MTs ([Fig. 1A](#f1-crt-2017-598){ref-type="fig"}). In addition, no difference in iDFS or OS was observed between patients with WT and 1MT of *PIK3CA* ([Fig. 1A](#f1-crt-2017-598){ref-type="fig"} and [B](#f1-crt-2017-598){ref-type="fig"}).

Regarding *PIK3CA/AKT1* mutation, patients with 1MT exhibited better iDFS (adjusted HR, 0.269; p=0.011) and OS (adjusted HR, 0.151; p=0.002) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 1C](#f1-crt-2017-598){ref-type="fig"} and [D](#f1-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA/AKT1* exhibited a better OS than those with 2MTs (adjusted HR, 0.181; p=0.006) ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 1D](#f1-crt-2017-598){ref-type="fig"}), but no significant difference in iDFS. While patients with 1MT in *PIK3CA/AKT1* showed a trend toward better iDFS than patients with WT *PIK3CA/AKT1* (p=0.054) ([Fig. 1C](#f1-crt-2017-598){ref-type="fig"}), the OS of patients with 1MT in *PIK3CA/AKT1* was not significantly different than in patients with WT *PIK3CA/AKT1* ([Fig. 1D](#f1-crt-2017-598){ref-type="fig"}).

### 2) ER-positive patients (210 cases)

Regarding the *PIK3CA* gene, no significant difference in iDFS was observed among ER+ patients with WT, 1MT, and 2MTs in *PIK3CA* ([Fig. 2A](#f2-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA* had a trend of better OS than those with 2MTs in *PIK3CA* (adjusted HR, 0.203; p=0.058) ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 2B](#f2-crt-2017-598){ref-type="fig"}). However, there was no difference in OS for patients with WT and 1MT in *PIK3CA* ([Fig. 2B](#f2-crt-2017-598){ref-type="fig"}).

Regarding *PIK3CA/AKT1* mutation, ER+ patients with 1MT showed marginally better iDFS (adjusted HR, 0.322; p=0.051) and significantly better OS (adjusted HR, 0.195; p=0.026) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 2C](#f2-crt-2017-598){ref-type="fig"} and [D](#f2-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA/AKT1* exhibited better OS than those with 2MTs in *PIK3CA/AKT1* (adjusted HR, 0.167; p=0.022) ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 2D](#f2-crt-2017-598){ref-type="fig"}), but no significant difference in iDFS ([Fig. 2C](#f2-crt-2017-598){ref-type="fig"}). The iDFS and OS of patients with 1MT were not significantly different from those with WT *PIK3CA/AKT1* ([Fig. 2C](#f2-crt-2017-598){ref-type="fig"} and [D](#f2-crt-2017-598){ref-type="fig"}).

### 3) HER2-negative patients (210 cases)

Regarding *PIK3CA* mutation, HER2-- patients with 1MT exhibited significantly better iDFS (adjusted HR, 0.304; p=0.035) and OS (adjusted HR, 0.246; p=0.045) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 3A](#f3-crt-2017-598){ref-type="fig"} and [B](#f3-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA* had better OS (adjusted HR, 0.171; p=0.018) and showed a trend toward better iDFS (adjusted HR, 0.368; p=0.077) than those with 2MTs in *PIK3CA* ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 3A](#f3-crt-2017-598){ref-type="fig"} and [B](#f3-crt-2017-598){ref-type="fig"}). No difference in iDFS or OS was observed between patients with WT and 1MT in *PIK3CA* ([Fig. 3A](#f3-crt-2017-598){ref-type="fig"} and [B](#f3-crt-2017-598){ref-type="fig"}).

Regarding *PIK3CA/AKT1* mutation, HER2-- patients with 1MT had better iDFS (adjusted HR, 0.246; p=0.011) and OS (adjusted HR, 0.166; p=0.009) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 3C](#f3-crt-2017-598){ref-type="fig"} and [D](#f3-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA/AKT1* had better OS (adjusted HR, 0.161; p=0.010) and showed a trend toward better iDFS (adjusted HR, 0.376; p=0.069) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 3C](#f3-crt-2017-598){ref-type="fig"} and [D](#f3-crt-2017-598){ref-type="fig"}). There was no difference in iDFS and OS between patients with WT and 1MT in *PIK3CA/AKT1*.

### 4) Patients with high expression of *Ki67* (240 cases)

Regarding *PIK3CA* mutation, patients with high expression of *Ki67* and 1MT had better iDFS (adjusted HR, 0.198; p=0.009) and OS (adjusted HR, 0.096; p=0.001) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 4A](#f4-crt-2017-598){ref-type="fig"} and [B](#f4-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA* exhibited better OS than those with 2MTs in *PIK3CA* (adjusted HR, 0.114; p=0.002) ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 4B](#f4-crt-2017-598){ref-type="fig"}), with no significant difference in iDFS. The iDFS and OS of patients with 1MT were not significantly different than in patients with WT *PIK3CA* ([Fig. 4A](#f4-crt-2017-598){ref-type="fig"} and [B](#f4-crt-2017-598){ref-type="fig"}).

Regarding *PIK3CA/AKT1*mutation, patients with 1MT had better iDFS (adjusted HR, 0.191; p=0.007) and OS (adjusted HR, 0.093; p=0.001) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 4C](#f4-crt-2017-598){ref-type="fig"} and [D](#f4-crt-2017-598){ref-type="fig"}). Patients with WT *PIK3CA/AKT1* exhibited better OS (adjusted HR, 0.163; p=0.002) and a trend toward better iDFS (adjusted HR, 0.308; p=0.053) than those with 2MTs ([Table 3](#t3-crt-2017-598){ref-type="table"}, [Fig. 4C](#f4-crt-2017-598){ref-type="fig"} and [D](#f4-crt-2017-598){ref-type="fig"}). No difference in iDFS or OS was observed between patients with 1MT and WT *PIK3CA/AKT1*.

The prognosis between patients with mutant (hotspot and non-hotspot) and WT *PIK3CA* genes was also compared. Results showed that the iDFS and OS of patients with mutant *PIK3CA* was not significantly different from patients with WT *PIK3CA*, whether they were in the entire group or one of the three subgroups (ER+, HER2--, Ki67 high) ([S4](#SD4-crt-2017-598){ref-type="supplementary-material"}-[S7 Figs.](#SD7-crt-2017-598){ref-type="supplementary-material"}). Survival was also evaluated among patients with hotspot MT, non-hotspot MT and WT *PIK3CA*, and there was no difference in iDFS or OS ([S4](#SD4-crt-2017-598){ref-type="supplementary-material"}-[S7 Figs.](#SD7-crt-2017-598){ref-type="supplementary-material"}).

Survival between patients with mutant and WT *AKT1* was also evaluated, and there was no difference in iDFS or OS, whether they were in the entire group or one of the 3 subgroups ([S8 Fig.](#SD8-crt-2017-598){ref-type="supplementary-material"}). In addition, we compared iDFS and OS between patients with mutant (2MTs plus 1MT) or WT *PIK3CA/AKT1*, and no significant difference was observed ([S9 Fig.](#SD9-crt-2017-598){ref-type="supplementary-material"}).

Discussion
==========

This study provided new insight into the complexity of *PIK3CA* and *AKT1* mutations in Chinese breast cancer patients. *AKT1* mutations were detected in 3.6% of the 507 patients, and 4.9% (18/370) in the luminal subtype, which is similar to the 3.14% in the TCGA report \[[@b3-crt-2017-598]\]. *PIK3CA* mutations were detected in 46.5% of the 507 patients, and the hotspot mutations of *PIK3CA* were 39.4%. The frequency of *PIK3CA* mutations was 50.8% (188/370) in the luminal subtype, 41.8% (28/67) in the HER2-positive subtype, and 28.6% (20/70) in triple-negative breast cancer. This was similar to the *PIK3CA* mutation rates of BOLERO-2 trial, which was also detected via NGS \[[@b15-crt-2017-598]\]. In contrast, this was significantly higher than the *PIK3CA* mutation rates previously reported in a cohort of 729 Chinese women with breast cancer (28.3%) \[[@b11-crt-2017-598]\], as well as what was reported in a cohort of HER2-amplified metastatic breast cancer (24%) \[[@b14-crt-2017-598]\], which only detected hotspot mutations of *PIK3CA*. These results illustrated that NGS is a reliable method that can detect *PIK3CA* and *AKT1* mutations efficiently.

Also, we confirmed significant associations of *AKT1* mutations with clinicopathological and molecular characteristics, as well as *PIK3CA*mutations (whether hotspot or nonhotspot mutations). Both *AKT1* mutations and *PIK3CA* mutations were significantly associated with ER positive, PR positive and HER2 negative. *AKT1* mutations were also associated with high Ki67 expression. But Ki67 expression was not different among patients harboring hotspot mutation, non-hotspot mutation, or WT *PIK3CA*. This is consistent with the literature \[[@b6-crt-2017-598],[@b7-crt-2017-598],[@b12-crt-2017-598],[@b21-crt-2017-598]\].

The association between *PIK3CA*mutations and prognosis has been evaluated by many studies. However, results from these studies are still inconclusive. Some studies showed favorable \[[@b6-crt-2017-598],[@b7-crt-2017-598],[@b22-crt-2017-598]\], and others showed adverse \[[@b4-crt-2017-598],[@b6-crt-2017-598],[@b10-crt-2017-598],[@b14-crt-2017-598],[@b23-crt-2017-598]-[@b25-crt-2017-598]\], impacts of *PIK3CA* mutations on patient outcomes, while a significant number of reports did not show any prognostic significance \[[@b5-crt-2017-598],[@b8-crt-2017-598],[@b9-crt-2017-598],[@b11-crt-2017-598]-[@b13-crt-2017-598],[@b26-crt-2017-598]\]. In HER2-positive breast cancers, *PIK3CA* mutation was associated to poor prognosis in several studies \[[@b4-crt-2017-598],[@b25-crt-2017-598],[@b27-crt-2017-598]\], while the association of *PIK3CA* mutation with prognosis was not significantly in the FinHER trial \[[@b5-crt-2017-598]\]. *PIK3CA*mutation predicted poorer pathologic complete response (pCR) in patients with HER2+ breast cancer treated with neoadjuvant therapies \[[@b8-crt-2017-598],[@b9-crt-2017-598],[@b11-crt-2017-598],[@b28-crt-2017-598]\]; however, the association of *PIK3CA* mutation with pCR did not translate into DFS or OS outcomes \[[@b29-crt-2017-598],[@b30-crt-2017-598]\]. In the present study, patients with 1MT of the *PIK3CA* gene did not have significantly different iDFS or OS when compared to those with WT *PIK3CA*, whether they were in the entire group or all three subgroups (ER+, HER2--, Ki67 high). In addition, *PIK3CA* mutation was not associated with prognosis of HER2-positive patients (WT vs. MT, PDFS=0.268, POS=0.842, data not shown). These results demonstrated that single *PIK3CA* gene mutation might have little effect on the prognosis of breast cancer patients.

Preclinical models found *PIK3CA* mutations alone, compared to PTEN loss or *AKT1* mutations, can cause weaker or more inconsistent activation of PI3K-AKT signaling \[[@b31-crt-2017-598],[@b32-crt-2017-598]\]. If this signaling pathway accumulates more genetic alteration burden, it may lead to higher activation of the pathway. For prognosis, patients simultaneously harboring both *PIK3CA*mutation and PTEN loss had lower DFS and OS \[[@b12-crt-2017-598]\], which suggest that it may be possible to analyze the prognosis of patients according to the genetic alteration burden of PI3K-AKT pathway. In the present study, we compared prognosis of patients with 2MT of *PIK3CA/AKT1* to those with 1MT or wild-type *PIK3CA/AKT1*, which showed 2MT of *PIK3CA/AKT1* caused poorer iDFS and OS. Patients with 2MT of *PIK3CA* also had poorer prognosis. These results suggested that greater number of alterations in PI3K/AKT/mTOR pathway might cause higher activation of this pathway, which was associated with poor prognosis.

Drugs targeting the PI3K/AKT/mTOR pathway in breast cancer are widely known, and some of them are approved for use in ER+ advanced breast cancer. Several studies have attempted to determine in which patients these drugs would achieve better clinical efficacy. An exploratory analysis using tumor samples from the BOLERO-2 trial showed that the efficacy of everolimus was largely independent of the most commonly altered genes (*PIK3CA*, FGFR1 and CCND1) in hormone receptor-positive and HER2-negative breast cancer. Subgroup analysis showed that *PIK3CA* exon-9 mutations were associated with a greater benefit from everolimus than exon-20 mutations \[[@b15-crt-2017-598]\]. However, another study using cellfree DNA from plasma samples from the BOLERO-2 trial showed that everolimus prolonged median progression-free survival in patients with *PIK3CA* H1047R and E545K/E542K mutations to a similar degree \[[@b33-crt-2017-598]\]. These different results demonstrate that more accurate and effective biomarkers are still needed to determine the efficacy of drugs targeting the PI3K/AKT/mTOR pathway.

There are some limitations to the present study. This was a single-center retrospective study with a relatively small sample size. Although the present study found that a tumor mutational burden of 2-3 in *PIK3CA/AKT1* was associated with poorer outcomes, the sample size in this subgroup was relatively small compared to patients with WT or 1MT in *PIK3CA/AKT1*. The active burden for the entire PI3K/AKT1/mTOR pathway should be evaluated in a larger sample with a longer follow-up time.

In summary, *PIK3CA/AKT1* mutation was detected using NGS in 49.3% of breast cancer patients from a single hospital in West China, with the highest mutation frequency in the luminal cancers. *PIK3CA/AKT1* mutation was associated with positive ER, positive PR, or negative HER2 expression status. The prognosis of patients with one mutation in *PIK3CA* (or *PIK3CA/AKT1*) was not significantly different than in WT patients. Patients with a tumor mutational burden of 2-3 in *PIK3CA* (or *PIK3CA/AKT1*) had poorer prognosis in the entire group, or all 3 subgroups (ER+, HER2--, Ki67 high), particularly with respect to OS. These findings suggest that, in addition to mutation frequency, the tumor mutational burden of the *PIK3CA* and *AKT1* genes should also be considered, and that these could be potential prognostic biomarkers in breast cancer patients.
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![Impact of *PIK3CA/AKT1* mutations on the invasive disease-free survival (iDFS) and overall survival (OS) of 296 breast cancer patients with stage I-III and at least 5-year follow-up. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant burden: iDFS (A) and OS (B) for patients with wild-type (WT), one mutation (1MT), and two or three mutations (2MTs) of *PIK3CA*; iDFS (C) and OS (D) for patients with WT, 1MT, and 2MTs of *PIK3CA/AKT1*.](crt-2017-598f1){#f1-crt-2017-598}

![Impact of *PIK3CA/AKT1* mutations on the invasive disease-free survival (iDFS) and overall survival (OS) of 210 estrogen receptor (ER) positive breast cancer patients with stage I-III and at least 5-year follow-up. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant burden: iDFS (A) and OS (B) for patients with wild-type (WT), one mutation (1MT), and two or three mutations (2MTs) of PIK3CA; iDFS (C) and OS (D) for patients with WT, 1MT, and 2MTs of *PIK3CA/AKT1*.](crt-2017-598f2){#f2-crt-2017-598}

![Impact of *PIK3CA/AKT1* mutations on the invasive disease-free survival (iDFS) and overall survival (OS) of 210 human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with stage I-III and at least 5-year followup. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant burden: iDFS (A) and OS (B) for patients with wild-type (WT), one mutation (1MT), and two or three mutations (2MTs) of *PIK3CA*; iDFS (C) and OS (D) for patients with WT, 1MT, and 2MTs of *PIK3CA/AKT1*.](crt-2017-598f3){#f3-crt-2017-598}

![Impact of *PIK3CA/AKT1* mutations on the invasive disease-free survival (iDFS) and overall survival (OS) of 240 Ki67 high breast cancer patients with stage I-III and at least 5-year follow-up. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant burden: iDFS (A) and OS (B) for patients with wild-type (WT), one mutation (1MT), and two or three mutations (2MTs) of *PIK3CA*; iDFS (C) and OS (D) for patients with WT, 1MT, and 2MTs of *PIK3CA/AKT1*.](crt-2017-598f4){#f4-crt-2017-598}

###### 

*PIK3CA* and *AKT1* mutations in 507 breast cancer patients

  Gene                                                      Mutation type   Occurrence   Status   Hot-spot mutation   Frequency (%)
  --------------------------------------------------------- --------------- ------------ -------- ------------------- ---------------
  *AKT1*                                                    AKT1_E17K       17           Tumor    Yes                 3.4
                                                            AKT1_C77F       1            Tumor    No                  0.2
  *PIK3CA*^[a)](#tfn1-crt-2017-598){ref-type="table-fn"}^   PIK3CA_H1047R   121          Tumor    Yes                 23.9
                                                            PIK3CA_E545K    50           Tumor    Yes                 9.9
                                                            PIK3CA_H1047L   19           Tumor    Yes                 37.5
                                                            PIK3CA_E542K    14           Tumor    Yes                 27.6
                                                            PIK3CA_N345K    8            Tumor    No                  1.6
                                                            PIK3CA_E726K    7            Tumor    No                  1.4
                                                            PIK3CA_C420R    5            Tumor    No                  1.0
                                                            PIK3CA_G118D    3            Tumor    No                  0.6
                                                            PIK3CA_E365K    2            Tumor    No                  0.4
                                                            PIK3CA_P471L    2            Tumor    No                  0.4
                                                            PIK3CA_Q546K    2            Tumor    No                  0.4
                                                            PIK3CA_T1025A   2            Tumor    No                  0.4
                                                            PIK3CA_G1049R   2            Tumor    No                  0.4

36 additional PIK3CA variants (tumor status) were identified with 1 occurrence: PIK3CA_C420DEL, PIK3CA_D454DEL, PIK3CA_D454N, PIK3CA_D527N, PIK3CA_D830H, PIK3CA_E103DEL, PIK3CA_E418K, PIK3CA_E545D, PIK3CA_E545Q, PIK3CA_E600K, PIK3CA_E674Q, PIK3CA_E722Q, PIK3CA_E798K, PIK3CA_E81K, PIK3CA_E970K, PIK3CA_E9DE, PIK3CA_G364R, PIK3CA_H1065L, PIK3CA_HC491DEL, PIK3CA_I102F, PIK3CA_K111E, PIK3CA_K485N, PIK3CA_KI111N, PIK3CA_L422W, PIK3CA_M16I, PIK3CA_N1044I, PIK3CA_N1068INS, PIK3CA_N345I, PIK3CA_p.Cys472_Leu473insPheGlu, PIK3CA_P104DEL, PIK3CA_P449DEL, PIK3CA_Q546E, PIK3CA_Q75E, PIK3CA_R115L, PIK3CA_T1052K PIK3CA_V101DEL.

###### 

The clinical and pathological features of patients with PIK3CA and AKT1 mutations

  Characteristic                     *AKT1* mutation   p-value                                                *PIK3CA* mutation   p-value     *PIK3CA/AKT1* mutation burdens                            p-value                  
  ---------------------------------- ----------------- ------------------------------------------------------ ------------------- ----------- --------------------------------------------------------- ----------- ------------ ---------------------------------------------------------
  **Age (yr)**                       50.9±9.3          0.72^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^    50.8±10.1           51.2±8.3    0.24^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^       50.6±9.4    50.9±9.9     0.20^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
  **Menopausal status**                                0.60^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.92^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.92^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Premenopausal                     9 (50.0)                                                                 88 (44.0)           17 (47.2)   0.720^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      17 (43.6)   95 (45.0)    0.856^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Postmenopausal                    9 (50.0)                                                                 112 (56.0)          19 (52.8)                                                             22 (56.4)   116 (55.0)   
  **Breast cancer family history**                     0.53^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.29^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.79^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Yes                               1 (5.6)                                                                  4 (2.0)             2 (5.6)     0.225^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      0           7 (3.3)      0.600^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   No                                17 (94.4)                                                                198 (98.9)          34 (94.4)                                                             39 (100)    204 (96.7)   
  **Pathological type**                                0.59^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.68^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.98^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   DCIS                              0                                                                        1 (0.5)             1 (2.8)     0.382^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      0           2 (0.9)      1.0^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   IDC                               17 (94.4)                                                                192 (96.0)          34 (94.4)                                                             38 (97.4)   201 (95.3)   
   Other IBC                         1 (5.6)                                                                  7 (3.5)             1 (2.8)                                                               1 (2.6)     8 (3.8)      
  **Tumor grade**                                      0.06^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.14^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.04^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   1                                 1 (5.6)                                                                  10 (5.0)            1 (2.8)     0.149^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      3 (7.7)     8 (3.8)      0.066^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   2                                 10 (55.6)                                                                67 (33.5)           9 (25.0)                                                              19 (48.7)   64 (30.3)    
   3                                 7 (38.9)                                                                 108 (54.0)          26 (72.2)                                                             15 (38.5)   126 (59.7)   
   Unknown                           0                                                                        15 (7.5)            0                                                                     2 (5.1)     13 (6.2)     
  **T stage**                                          0.08^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.64^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.59^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Tis/T1                            9 (50.0)                                                                 70 (35.0)           10 (27.8)   0.395^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      11 (28.2)   75 (35.5)    0.495^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   T2                                7 (38.9)                                                                 118 (59.0)          24 (66.7)                                                             26 (66.7)   122 (57.8)   
   T3                                0                                                                        7 (3.5)             0                                                                     0           7 (3.3)      
   T4                                2 (11.1)                                                                 5 (2.5)             2 (5.6)                                                               2 (5.1)     7 (3.3)      
   Tx                                0                                                                        0                   0                                                                     0           0            
  **Lymph node involvement**                           0.90^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.46^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.56^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   N0                                9 (50.0)                                                                 95 (47.5)           13 (36.1)   0.436^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      15 (38.5)   99 (46.9)    0.713^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   N1                                7 (38.9)                                                                 66 (33.0)           17 (47.2)                                                             17 (43.6)   72 (34.1)    
   N2                                1 (5.6)                                                                  25 (12.5)           4 (11.1)                                                              4 (10.3)    26 (12.3)    
   N3                                1 (5.6)                                                                  14 (7.0)            2 (5.6)                                                               3 (7.7)     14 (6.6)     
  **Metastasis**                                       0.17^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                    0.13^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.598^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   M0                                17 (94.4)                                                                200 (100)           36 (100)                                                              39 (100)    210 (99.5)   
   M1                                1 (5.6)                                                                  0                   0                                                                     0           1 (0.5)      
  **Molecular subtypes**                               0.001^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                   0.003^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                               \< 0.001^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Luminal A                         6 (33.3)                                                                 25 (12.5)           4 (11.1)    0.169^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      10 (25.6)   23 (10.9)    0.140^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Luminal B1                        12 (66.7)                                                                110 (55.0)          13 (36.1)                                                             21 (53.8)   112 (53.1)   
   Luminal B2                        0                                                                        28 (14.0)           8 (22.2)                                                              3 (7.7)     33 (15.6)    
   HER2+                             0                                                                        21 (10.5)           7 (19.4)                                                              3 (7.7)     25 (11.8)    
   TN                                0                                                                        16 (8.0)            4 (11.1)                                                              2 (5.1)     18 (8.5)     
  **ER**                                               0.001^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                   \< 0.001^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                            \< 0.001^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Positive                          18 (100)                                                                 158 (79.0)          25 (69.4)   0.206^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      34 (87.2)   163 (77.3)   0.163^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Negative                          0                                                                        42 (21.0)           11 (30.6)                                                             5 (12.8)    48 (22.7)    
  **PR**                                               0.001^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                   0.013^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                               0.005^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Positive                          18 (100)                                                                 147 (73.5)          21 (68.3)   0.064^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      30 (76.9)   152 (72.0)   0.529^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Negative                          0                                                                        53 (26.5)           15 (31.7)                                                             9 (23.1)    59 (28.0)    
  **HER2**                                             0.003^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                   0.039^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                               0.021^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   Positive                          0                                                                        49 (24.5)           15 (41.7)   0.033^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      6 (15.4)    58 (27.5)    0.112^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Negative                          18 (100)                                                                 151 (75.5)          21 (58.3)                                                             33 (84.6)   153 (72.5)   
  **Ki67**                                             0.001^[a)](#tfn2-crt-2017-598){ref-type="table-fn"}^                                   0.62^[b)](#tfn3-crt-2017-598){ref-type="table-fn"}^                                0.031^[c)](#tfn4-crt-2017-598){ref-type="table-fn"}^
   High                              10 (55.6)                                                                163 (81.5)          30 (83.3)   0.793^[d)](#tfn5-crt-2017-598){ref-type="table-fn"}^      27 (69.2)   175 (82.9)   0.046^[e)](#tfn6-crt-2017-598){ref-type="table-fn"}^
   Low                               8 (44.4)                                                                 37 (19.5)           6 (16.7)                                                              12 (30.8)   36 (17.1)    

Value are presented as number (%). MT, mutation; 2MTs, 2 or 3 mutations; 1MT, 1 mutation; DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; IBC, invasive breast cancer; HER2, human epidermal growth factor receptor 2; TN, triple negative subtype; Luminal B1, luminal B-HER2 negative subtype; Luminal B2, luminal B2-HER2 positive subtype; HER2+, HER2 positive subtype; ER, estrogen receptor; PR, progesterone receptor.

p-value for mutant and WT *AKT1*,

p-value for hotspot mutant, non-hotspot mutant and WT *PIK3CA*,

p-value for 2MTs, 1MT and WT of *PIK3CA/AKT1*,

p-value for hotspot and non-hotspot mutant *PIK3CA*,

p-value for 2MTs and 1MT of *PIK3CA/AKT1*.

###### 

Cox multivariate risk model for patients with different mutant burdens (stage I-III and at least 5-year follow-up)

                          *PIK3CA* mutation                                   *PIK3CA/AKT1* mutation                                                                                                                                                                               
  ----------------------- --------------------------------------------------- ------------------------ --------------------------------------------------- ------- --------------------------------------------------- ------- --------------------------------------------------- -------
  **Total (n=296)**                                                                                                                                                                                                                                                                
   2MTs                   1^[a)](#tfn7-crt-2017-598){ref-type="table-fn"}^    0.119                    1^[a)](#tfn7-crt-2017-598){ref-type="table-fn"}^    0.053   1^[b)](#tfn8-crt-2017-598){ref-type="table-fn"}^    0.056   1^[b)](#tfn8-crt-2017-598){ref-type="table-fn"}^    0.008
   1MT                    0.344 (0.119-0.994)                                 0.049                    0.222 (0.063-0.787)                                 0.020   0.269 (0.098-0.742)                                 0.011   0.151 (0.045-0.510)                                 0.002
   WT                     0.500 (0.177-1.414)                                 0.191                    0.221 (0.061-0.799)                                 0.021   0.452 (0.169-1.211)                                 0.114   0.181 (0.053-0.612)                                 0.006
  **ER+ (n=210)**         1^[c)](#tfn9-crt-2017-598){ref-type="table-fn"}^    0.402                    1^[c)](#tfn9-crt-2017-598){ref-type="table-fn"}^    0.165   1^[d)](#tfn10-crt-2017-598){ref-type="table-fn"}^   0.125   1^[d)](#tfn10-crt-2017-598){ref-type="table-fn"}^   0.053
   1MT                    0.444 (0.133-1.482)                                 0.187                    0.333 (0.073-1.518)                                 0.155   0.322 (0.104-1.003)                                 0.051   0.195 (0.046-0.820)                                 0.026
   WT                     0.588 (0.180-1.921)                                 0.379                    0.203 (0.039-1.052)                                 0.058   0.537 (0.178-1.624)                                 0.271   0.167 (0.036-0.774)                                 0.022
  **HER2-- (n=210)**      1^[e)](#tfn11-crt-2017-598){ref-type="table-fn"}^   0.105                    1^[e)](#tfn11-crt-2017-598){ref-type="table-fn"}^   0.056   1^[f)](#tfn12-crt-2017-598){ref-type="table-fn"}^   0.038   1^[f)](#tfn12-crt-2017-598){ref-type="table-fn"}^   0.017
   1MT                    0.304 (0.100-0.921)                                 0.035                    0.246 (0.062-0.972)                                 0.045   0.246 (0.084-0.721)                                 0.011   0.166 (0.044-0.636)                                 0.009
   WT                     0.368 (0.121-1.116)                                 0.077                    0.171 (0.039-0.741)                                 0.018   0.376 (0.131-1.079)                                 0.069   0.161 (0.040-0.643)                                 0.010
  **Ki67 high (n=210)**   1^[g)](#tfn13-crt-2017-598){ref-type="table-fn"}^   0.027                    1^[g)](#tfn13-crt-2017-598){ref-type="table-fn"}^   0.003   1^[h)](#tfn14-crt-2017-598){ref-type="table-fn"}^   0.022   1^[h)](#tfn14-crt-2017-598){ref-type="table-fn"}^   0.002
   1MT                    0.198 (0.059-0.662)                                 0.009                    0.096 (0.025-0.372)                                 0.001   0.191 (0.057-0.638)                                 0.007   0.093 (0.024-0.362)                                 0.001
   WT                     0.309 (0.094-1.014)                                 0.053                    0.114 (0.029-0.446)                                 0.002   0.308 (0.094-1.015)                                 0.053   0.163 (0.029-0.447)                                 0.002

Adjusted by *AKT1* mutation, age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy,

Adjusted by age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, ER, PR, HER2, Ki67, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy,

Adjusted by *AKT1* mutation, age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, PR, HER2, Ki67, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy,

Adjusted by age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, PR, HER2, Ki67, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy,

Adjusted by *AKT1* mutation, age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, ER, PR, Ki67, histological grade, surgery, radiotherapy, chemotherapy, and endocrine therapy,

Adjusted by age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, ER, PR, Ki67, histological grade, surgery, radiotherapy, chemotherapy, and endocrine therapy,

Adjusted by *AKT1* mutation, age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, ER, PR, HER2, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy,

Adjusted by age at diagnosis, menopause at diagnosis, tumor size, lymph node metastasis, ER, PR, HER2, histological grade, surgery, radiotherapy, chemotherapy, endocrine therapy, and target therapy.
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